

Urgent Field Safety Notice

Commercial Name of Affected Product: Nellix® EndoVascular Aneurysm Sealing System (all model numbers / serial numbers)

Date: January 4, 2019

Type of Action: Return of the Affected Product

Dear Customer,
cc Chairman Medical Board and Relevant Head of Departments

Details of affected devices

Endologix is issuing a voluntary recall for the Nellix® EndoVascular Aneurysm Sealing System (the "Nellix System").

Description of the problem

Endologix is voluntarily ceasing sales, effective immediately, and requesting the return of all unused Nellix Systems due to adverse events including migration, Type 1 endoleak, and aneurysm enlargement, which Endologix predominately attributes to use outside of the current indications. Endologix has previously issued several FSNs to update labeling, detail procedural best practices, and train on appropriate use.

In order to ensure optimal outcomes for patients, unrestricted sales and use of the Nellix System will cease immediately, and the product will only be available for use under clinical protocol with pre-screened patients that adhere to the current indications.

This decision is concordant with the recently published European Society for Vascular Surgery Practice Guidelines.

FIELD SAFETY CORRECTIVE ACTION INSTRUCTIONS

ACTION TO BE TAKEN BY MEDICAL STAFF

1. Please reference the attached list of affected model numbers.
2. Please immediately stop using and/or distributing the devices.
3. Please review your inventory, complete, and return the attached Acknowledgement and Inventory Form. For those in the European Economic Area email to FSCA-europe@endologix.com or for all other geographies email to customerservice@endologix.com.
4. In the cases where unused devices are to be returned, Endologix will provide separate instructions based on the institution and location.
5. Please share this notification with other relevant personnel in your organization. Please consider end users, physicians, risk managers, warehouses, and supply chain/distribution centers in the circulation of this notice.

INSTRUCTIONS FOR DISTRIBUTORS

If you are a distributor, please follow actions 1-5 above. Furthermore, please provide this field safety notice to all of your customers who have received the Nellix System. Each of your customers is then required to complete the Acknowledgement and Inventory Form and return it to you. Endologix then requires you to return a consolidated Acknowledgement and Inventory Form to Endologix by email to [January 2019](mailto:FSCA-</p></div><div data-bbox=)

Europe@endologix.com for the European Economic Area or for all other geographies email to customerservice@endologix.com.

Contact at Endologix


For guidance and support concerning this issue, please contact your Endologix representative or Endologix Customer service at eucustomerservice@endologix.com or phone number +31 88 116 91 01 in the European Economic Area or for all other geographies at customerservice@endologix.com or phone number +001 800 983 2284.

Re-interventions

If you are aware of a patient requiring a re-intervention with the Nellix System, Endologix will work with you and the competent authority of your country to determine the best path forward in the interest of patient safety. If this occurs, please contact your local sales representative who will work with the Endologix Medical Affairs team.

Patient safety is our top priority, and we are committed to delivering safe and effective therapies to our customers. We appreciate your time and attention in reading this important notification.

Yours Sincerely,



Matt Thompson, MD
Chief Medical Officer